ELUT - elutia.com Enterprise Value

Official company branding of Elutia Corporation (ELUT)

Elutia Inc. is expanding its CanGaroo B2B supply network of biological sheaths for pacemakers across US medical centers. The company is also implementing EluPRO antibacterial systems to mitigate infection risks and drive profit growth, as reflected in the price trend chart on GURU.Markets, where the indicator stands at 26.53. The business relies on complex technical processes while resisting pressure from corporate behemoths and emerging biotech developments.

ELUT (Elutia Corp) Total Company Value history from 11/23/2025 to 10/28/2026

ELUT (Elutia Inc.): analytical breakdowns and indicator data

- price and consensus price forecast:
Price Chart Elutia Inc|ELUT - Consensus Target
- market capitalization data:
Market Capitalization Elutia|ELUT - Real Price to Acquire Entire Company
- book capitalization data:
Book Price of a Share Elutia|ELUT - Company Book Value|Market Cap to Net Assets Ratio elutia.com|ELUT - Company Total Assets
- debt and liquidity data:
Debt to Capital Elutia Inc.|ELUT - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio elutia.com|ELUT - Company Aggregate Debts|Debts to Net Assets Elutia|ELUT - Company Long-Term Debts|Company Current Liabilities Elutia
General company analysis:ELUT (Elutia Inc)
Original product of Elutia Inc

Enterprise Value (EV) represents the total acquisition cost of a business, combining market capitalization with net debt. This calculation allows for an assessment of real financial obligations and assets by eliminating distortions caused by cash holdings. By analyzing changes in EV levels, an investor can track the dynamics of the company's market recognition. For Elutia Inc. (ELUT), this metric reflects the value of intellectual capital within the biomedical scaffold sector. The indicator demonstrates how the market values R&D investments in regenerative medicine.

Competitor analysis for Elutia Inc.

ISRG - Total Company Value|Danaher Corp - Real Price to Acquire Entire Company|Becton Dickinson & Company (BDX) - Enterprise Value|STE - Real Price to Acquire Entire Company|WST (westpharma.com) - Aggregate Business Value|Total Company Value BAX|Real Price to Acquire Entire Company Masimo Corp|Stevanato - Enterprise Value|Total Enterprise Value Teleflex Corp (TFX)|MMSI - Enterprise Value|Business Value envistaco.com NVST|Enterprise Value ICUI (ICU Medical)|XRAY - Company Buyout Price|LMAT (LeMaitre) - Enterprise Value|AtriCure Medical (ATRC) - Real Price to Acquire Entire Company|STAA (STAAR Surgical Company) - Enterprise Value|Enterprise Value NAGE|Total Company Value ZimVie (ZIMV)|Total Company Value AngioDynamics Inc ANGO|Real Price to Acquire Entire Company Cerus Corp|Value Adjusted for Debt and Cash Teknova Inc TKNO|Enterprise Value MGRM (Monogram Technologies)|STSS: Company Buyout Price|Total Company Value infusystem.com|UTMD (Utah Medical Products Inc.) - Business Value|KRMD: Total Company Value|Company Buyout Price Nyxoah S.A (NYXH)|Real Price to Acquire Entire Company Microbot Medical Inc.|Aggregate Business Value PDEX (pro-dex.com)|Total Company Value Zentek|MLSS - Value Adjusted for Debt and Cash|NEXGEL, Inc - Real Price to Acquire Entire Company|RVP: Enterprise Value|HBIO (Harvard Bioscience) - Total Company Value|femasys.com (FEMY) - Real Price to Acquire Entire Company|Enterprise Value MHUA (Meihua Medical Technologies)|Total Enterprise Value POAI|Total Company Value Callan JMB Inc CJMB|Business Value Atrion Corporation Inc. ATRI|Real Price to Acquire Entire Company NeuroMetrix, Inc. (NURO)